Publication:
Treatment endpoints for chronic hepatitis D

Simple item page
dc.contributor.coauthorMetin, Olga
dc.contributor.kuauthorZeybel, Müjdat
dc.contributor.kuauthorYurdaydın, Cihan
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-12-29T09:41:21Z
dc.date.issued2023
dc.description.abstractManagement of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD. In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. For this, we took guidance from CHB studies and tried to make suggestions which differed according to finite versus prolonged treatment durations and also took into account the different characteristics of the new compounds.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.volume43
dc.identifier.doi10.1111/liv.15447
dc.identifier.eissn1478-3231
dc.identifier.issn1478-3223
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85139790045
dc.identifier.urihttps://doi.org/10.1111/liv.15447
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23598
dc.identifier.wos867490000001
dc.keywordsChronic hepatitis D
dc.keywordsPrimary endpoints
dc.keywordsSecondary endpoints
dc.keywordsTreatment
dc.languageen
dc.publisherJohn Wiley and Sons Inc
dc.sourceLiver International
dc.subjectGastroenterology
dc.subjectHepatology
dc.titleTreatment endpoints for chronic hepatitis D
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorZeybel, Müjdat
local.contributor.kuauthorYurdaydın, Cihan

Files

Collections

Publications without Fulltext